Fenwick publishes a quarterly study of VC deal activity in various areas. The most recent life sciences report can be found here: http://www.fenwick.com/vctrends/LS_VC_Survey_2006.htm?WT.mc_id=LSVCS_032707_e-mail-corp
Earnouts are rife with controversy. While they are popular in today’s deal market, and most parties see them as a creative remedy to bridge a pricing or funding gap, the majority fail and result in disputes. Assuming the best of intentions to honor the original agreement, it is impossible to predict all of the parameters that may impact a future earnout potential. A recent decision by the US District Court for E.D. of Wisconsin, Didion Milling, Inc. v. Agro Distribution, LLC (2007 WL 702808) is a good primer of some the issues that may need to be tested at the purchase agreement stage.
The earnout here was based on a net cash flow determination, where the APA provided a list of guidelines on how it would be calculated, including a reference that GAAP would be used. Despite a provision in the APA that the agreement could not be assigned, the buyer assigned the agreement to another entity, which in turn assigned it again, so that the party owing the earnout was not the original buyer. Since the earnout was based on a calculation of the original business acquired, this complicated the earnout calculation not to seller’s liking.
One issue was that net cash flow was supposed to take into account after-tax numbers. The original buyer was a corporation, so it paid its own taxes. The ultimate successor was an LLC, a pass-thru, so the tax rates and rules would be different, and would not be paid by the business but by its members. This created ambiguity as to whether taxes should be included, and if so, how much. This is probably something that, now with 20-20 hindsight, should be addressed specifically in the purchase agreement.
The parties disagreed as to the interest deduction against the earnout calculation, and whether the buyer’s overall cost of capital can be used to apply across the board. Again, probably something that can be spelled out in advance, at least by plugging in numbers for min/max.
Finally, this case also involves a claim for good faith and fair dealing, which is common in earnout cases. To provide the flavor what is usually alleged, the plaintiffs claimed that each of the following was a separate reason to find bad faith: (1) buyer acquired the business aware that seller had not consented to the assignment; (2) buyer focused on reselling the business rather than operating it; (3) buyer failed to provide seller with monthly financial statements; (4) buyer failed to provide seller with the documentation necessary to support calculation of net cash flow; and (5) buyer engaged in “sharp dealing” by assessing taxes, charging interest, and early expensing of payment. The court rejected all of these as a matter of law.
A couple of these deserve comment. On the consent issue, the court noted that while a good faith claim did not work here because the ultimate buyer had no privity with the seller under the original seller, there could be a claim for intentional interefence with a contract (which was not alleged here).
On “sharp dealing”, the court explained that a party may violate the duty of good faith by taking deliberate advantage of another party’s oversight. Such sharp dealing may or may not be actionable in tort. Actions such as avoiding an unbargained for expense or obtaining an advantage by way of exploiting superior knowledge do not, however, constitute sharp dealing or a breach of the duty of good faith.
While the venture market still seems flush with cash, a number of recent litigations involving venture firms (such as the Hummer Winblad case now in seemingly constant discussion) are driving the market to seek additional protections from their portfolio companies upon investment and afterwards.
In particular, some investors are now asking for indemnification from the company akin to the measures in an acquisition agreement. Companies looking to oppose these provisions should know that they are generally rare. While an indemnity is market where the deal presents some liquidity to the founders or other investors. this is not common in the venture context. The VC investors typically have board seats, observation and information rights and strong covenants, so they are in a position to see how the money is spent. If they don't have then, this presents a bargaining chip for the company in exchange for the indemnity being sought. They also have the right to sue the company for breach of the reps or fraud while there is still money to pay the claim. Unlike an M&A deal, venture round docs usually don't have exclusive remedy clauses.
A later stage financing certainly is more likely to give concern to the investor about the unknown that cannot adequately be tested through due diligence, but it would be unfair to shift that risk to the founders. If I am a VC asking for this provision and getting it regularly, I have to ask kind of company (and founder team) am I investing in if they will accept those terms. The
better the terms for the VC, the more apparently becomes the adverse selection problem.
One way to deal with the issue is to ask the investors their specific concerns. If there is a known problem, such as a litigation, a 409A problem, etc., that can be dealt with through traunches, escrow etc, without personally impinging on the Founders . The NVCA model docs address this issue parenthetically by having certain reps be made by the Founders, where the "Founder's liability for breaches of any provisions of this Section 3 shall be limited to the then current fair market value [as determined in good faith by the board of directors of the Company and such Founder [may, in his sole discretion, discharge such liability by the surrender of such shares or the payment of cash] (note FN1 and FN2 below from the docs). The NVCA docs are intended as a fair starting point for a Series A round, and they do not contemplate an indemnity. Finally, another approach may be to allow the indemnity, but to limit all recourse to the Founder's shares. The risk here, of course, is the precedent for the next round.
[1] Founders' representations are controversial and may elicit significant resistance. They are more common in the Northeast and counsel should be warned that they may not be well received elsewhere.
They are more likely to appear if Founders are receiving liquidity from the transaction or if there is heightened concern over intellectual property (e.g., the Company is a spin-out from an academic institution
or the Founder was formerly with another Company whose business could be deemed competitive with the Company). Founders' representations are not common in subsequent rounds, even in the Northeast, where risk is viewed as significantly diminished and fairly shared by the investors rather than being disproportionately borne by the Founders.
[2] Investors should consider whether cash is an acceptable remedy; the cash value of the shares is likely to be low, particularly if there has been a breach of a rep or warranty. In addition, if the Investors require the surrender of shares rather than cash, they should also consider whether to include Preferred Stock, as well, if the Founder owns shares of Preferred.
What do VCs really want from their CEOs? A recent study by VentureOne shows that #1 is sales and marketing, followed by operations leadership, financial management and product development.
The study summary can be found here
This study of VCs and CEOs reflects some interesting, but not surprising statistics about board members in startups and tech companies.
A recent decision by the Massachusetts Supreme Judicial Court (SJC) found that in a close corporation context, the estate of one of the company’s founders that was a minority shareholder was not entitled to a buyout. See here for the opinion: http://www.socialaw.com/slip.htm?cid=16741&sid=120
The court stated that in a freeze-out situation, the buyout is not the only reasonable remedy. Instead, since the freeze-out denies the minority’s “reasonable expectations of benefit” of being a stockholder, the remedy should, to the extent possible, restore to the minority shareholder those benefits reasonably expected, but not received because of the breach.
The court explained that “in ordering the defendants to purchase the plaintiff’s stock at the price of her pro rata share of the company, the judge created an artificial market for the plaintiff’s minority share of a close corporation — an asset that, by definition, has little or no market value.” This is a very interesting position, considering all of the ado over 409A and stock option valuations for startup companies in the last few years.
A recent Massachusetts appeals court decision defines Mass law regarding defacto mergers and successor liability regarding environmental claims. The case can be found here: http://www.socialaw.com/slip.htm?cid=16545&sid=119
This case summarizes as follows the Mass law regarding defacto mergers:
Factors considered in determining whether a sale should be treated as a de facto merger are: “whether (1) there is a continuation of the enterprise of the seller corporation so that there is a continuity of management, personnel, physical location, assets, and general business operations; whether (2) there is a continuity of shareholders which results from the purchasing corporation paying for the acquired assets with shares of its own stock, this stock ultimately coming to be held by the shareholders of the seller corporation so that they become a constituent part of the purchasing corporation; whether (3) the seller corporation ceases its ordinary business operations, liquidates, and dissolves as soon as legally and practically possible; and whether (4) the purchasing corporation assumes those obligations of the seller ordinarily necessary for the uninterrupted continuation of normal business operations of the seller corporation.” Cargill, Inc. v. Beaver Coal & Oil Co., 424 Mass. 356, 359-360 (1997).
The court noted that one key is looking at continuity of management, employees and shareholders.
This decision is also instructive on the liability a buyer would assume pursuant to express language in a purchase agreement. The court found that buyer’s assumption of liabilities of seller “as then existing” pursuant to an asset purchase agreement was not sufficient to hold that buyer assumed CERCLA liability then unknown.
Most startups suffer high staff turnover, and their CXO’s are no exception. In the short but exciting lifespan of a venture backed startup, it is not unusual to see two or more CEOs and other CXOs rotate through the company to navigate it through the rough waters of going from idea to beta to market, and so on.
See the following link for a recent whitepaper that honestly discusses this point: http://www.pwcmoneytree.com/exhibits/RitesOfPassageArticle.pdf
While experienced, or “repeat”, CEOs are less prone to find themselves in this position, most early stage executives may find that the investors want to make a change or bring in a more specialized industry player with execution success. Founder teams that plan to seek investment capital are wise to plan for such a potential change and position themselves in the company where they could have a long-tenured position. Discussing this issue upfront with their investors and negotiating appropriate employment agreements is always a good idea to give both sides the comfort and incentive necessary for promoting the overall success of the business and gaining the investors’ trust.
The PWCMoneyTree Survey for Q4 2006 shows in increase in deals over the last 5 years. VCs invested over $25 billion in 3,416 deals in 2006, a 10 percent increase in deal volume and a 12 percent increase in dollar value. 2006 had significant growth in life sciences, biotech and medical devices, and a strong year for Media/Entertainment, Energy and Web 2.0 companies. In particular, Media and Entertainment companies raised $1.6 billion in 299 deals (compared to 2005 when $1 billion went into180 deals). Telecom raised $2.6 billion, with wireless accounting for 44 percent of the Telecom sector deal size. The study and related links can be found here: http://www.pwcmoneytree.com/moneytree/index.jsp
New England had over 400 deals in 2006 (11% of national deal volume in deal size), second only to Silicon Valley, which had over 1100 deals (35% of national deal volume in deal size).
Another report provides valuation tracking going back to 1997. The average pre-money valuation for “Early Stage” (i.e. Series A) seed level deals for Q3′06 was just over $6M, with a typical seed round around $5.6M. Expansion Stage deals (i.e. Series B or Series C) had an average pre-money valuation of $54M, with an average deal size of $13M. The report can be read here http://www.pwcmoneytree.com/exhibits/Valuations_95_06Q3_12MonthRollingAvgs.xls
